Protara Therapeutics, Inc. (TARA)
 NASDAQ: TARA · Real-Time Price · USD
 5.21
 +0.07 (1.36%)
  Oct 31, 2025, 11:28 AM EDT - Market open
Protara Therapeutics Employees
As of December 31, 2024, Protara Therapeutics had 33 total employees, including 28 full-time and 5 part-time employees. The number of employees increased by 6 or 22.22% compared to the previous year.
Employees 
 33
Change (1Y) 
 6
Growth (1Y) 
 22.22%
Revenue / Employee 
 n/a
Profits / Employee 
 -$1,541,273
Market Cap 
201.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 33 | 6 | 22.22% | 
| Dec 31, 2023 | 27 | 2 | 8.00% | 
| Dec 31, 2022 | 25 | -6 | -19.35% | 
| Dec 31, 2021 | 31 | 4 | 14.81% | 
| Dec 31, 2020 | 27 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
TARA News
- 4 weeks ago - Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Protara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Protara Therapeutics Announces Addition to the Russell 3000® Index - GlobeNewsWire
- 5 months ago - Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - GlobeNewsWire
- 6 months ago - Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - GlobeNewsWire
- 6 months ago - Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - GlobeNewsWire